Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
about
Blood brain barrier: a challenge for effectual therapy of brain tumorsDesigner lipids for drug delivery: from heads to tails.Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy.Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopyMechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release.Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.Tumor-targeting drug delivery of new-generation taxoids.In search of a cytostatic agent derived from the alkaloid lycorine: synthesis and growth inhibitory properties of lycorine derivativesDentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-κB Inhibition.2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancerUpdate on taxane development: new analogs and new formulationsImproved biochemical strategies for targeted delivery of taxoidsPhase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery.Fluorine-Containing Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery.Taxane anticancer agents: a patent perspective.Exploration of fluorine chemistry at the multidisciplinary interface of chemistry and biology.Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism.Paclitaxel Nano-Delivery Systems: A Comprehensive Review.Synthetic low-density lipoprotein (sLDL) selectively delivers paclitaxel to tumor with low systemic toxicity.Silicate esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential.Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise.Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.Lipid-Drug Conjugate for Enhancing Drug Delivery.Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Novel Taxoid-Based Tumor-Targeting Drug Conjugates.Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine.Design, Synthesis, and Biological Evaluations of Asymmetric Bow-Tie PAMAM Dendrimer-Based Conjugates for Tumor-Targeted Drug Delivery.
P2860
Q28081947-624608C0-904B-49A0-9331-A4AC5B5AF752Q30402374-BDA313A2-75D9-4AEC-8216-681FDBDBB34CQ33830347-93172A09-F8FE-4F83-A86F-702656D6C2E5Q33894592-27AFCAFE-7F7A-4207-B4C4-C6754F9A7C41Q34484310-ED3C960C-F29D-4979-BAE3-83BEEA0828E8Q34565264-1455FDFE-97AF-4CC5-8816-70ACFE4C1708Q35003419-4D663372-D859-45CA-A4CA-E74CC6F20911Q35765100-F4C15BA9-321E-4C65-A43E-5F056D4B3DA0Q36057981-5078D0CE-3156-4F58-8E7D-EC626E537F00Q36317900-B2C67792-FECF-4F2F-8129-6FF21568B3F8Q36468079-1F3B6C5F-7CEE-49A7-820A-29F18A42142AQ36470377-A1A453B9-CE45-45F6-A403-5CCE844A64B7Q36642502-7BF7404B-7DE3-4D6B-9626-A3B5FE90CFC1Q36696098-4FECAE90-AE97-4962-B6D3-56A9AA5AD2ADQ36742881-7271F8B0-9A0A-4097-A354-570B6D6EA1AAQ37074780-E1E11655-EE7C-465C-8502-7F52F95643C6Q37087888-6D315DFD-418E-41BE-BFF1-E0D97439B879Q37118460-EA3306B5-C9F7-44E4-B2A6-FA0A288E67C7Q37139330-713E28B0-9A43-4C3B-9227-01085EE70B04Q37250009-EFCEDE39-4132-4224-ADB9-DA5163936064Q37588319-689C78D3-1DC5-4448-B451-3B22993E31E2Q37697357-FF2F54F6-AC42-4402-ABA1-C41F5EA3645CQ37959975-9F4E7190-4400-45CA-A154-74BF4DDF2412Q38799790-E611FCA9-32DF-44C7-A661-80ABD48A81BEQ39083391-ED88C450-7B37-4740-B6AC-1BC7995BCEF8Q41225670-96527F12-52ED-41D7-906D-D6B4F395EDB2Q41897007-69C2197C-30A7-4A1A-9463-0993610F76B5Q42087874-B1DBC3E2-38C4-4583-9795-FA08A58B696FQ45056901-2ABF78A7-E28E-4855-AD6D-890105A2DE9DQ54957223-D4554836-DA2B-4131-9AEF-2E3AB37354C1
P2860
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
@en
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
@nl
type
label
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
@en
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
@nl
prefLabel
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
@en
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
@nl
P2093
P1476
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
@en
P2093
Anthony FH
Bradley MO
Chander MC
Devanesan P
Hemamalini S
Horwitz SB
Swindell CS
P304
P407
P577
2001-10-01T00:00:00Z